Vancomycin plus rifampicin for methicillin-resistant Staphylococcus aureus pneumonia benefits only those who have no development of rifampicin resistance during treatment.
Tan
Che-Kim
CK
Lai
Chih-Cheng
CC
Lin
Sheng-Hsiang
SH
Hsueh
Po-Ren
PR
D003422:Critical Care; D003428:Cross Infection / Q000175:diagnosis / Q000188:drug therapy; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D011023:Pneumonia, Staphylococcal / Q000175:diagnosis / Q000188:drug therapy*; D012293:Rifampin / Q000627:therapeutic use*; D018570:Risk Assessment; D016896:Treatment Outcome; D014640:Vancomycin / Q000627:therapeutic use*
D014640:Vancomycin; D012293:Rifampin